The checkpoint immunotherapy nivolumab (Opvido) has been listed on the PBS for locally advanced or metastatic non-small cell lung cancer and advanced (stage IV) clear cell variant renal cell carcinoma. The listings represent the first time patients with these cancers will have PBS reimbursed access to immuno-oncology therapy. Making the announcement at Sydney’s Royal North ...
Immunotherapy gets PBS listing for lung and renal cancer
3 Aug 2017